Elion Therapeutics is a cutting-edge biotechnology company dedicated to transforming the treatment of life-threatening IFIs. Elion was founded on the belief that mechanistic insights enable targeted optimizations of natural products. Today, Elion is advancing the first polyene antifungal rationally designed to mitigate toxicities and potentially transform the future of polyene therapy.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/17/24 | $81,000,000 | Series B |
AMR Action Fund Deerfield Management Company, L.P.  Illinois Ventures | undisclosed |
